Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Mostostal Warszawa shareholders approve issue of up to 100 million shares at extraordinary meeting

Mostostal Warszawa shareholders approve issue of up to 100 million shares at extraordinary meeting

BitgetBitget2026/11/03 12:34
  • Mostostal Warszawa shareholders authorized up to 100 million Series VI ordinary bearer shares at an extraordinary meeting on October 30, 2026.
  • Existing shareholders retain pre-emptive rights, with a November 30, 2026 record date; the share issue remains to be carried out.
  • Management expects ACCIONA to participate at PLN 2.75 per share; full subscription and payment would generate PLN 275 million gross.
  • ACCIONA's proposal for a larger capital increase did not receive sufficient shareholder support.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mostostal Warszawa SA published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss